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Abstract 
 
Background: The EORTC QLQ-C30 is one of the most commonly used 
measures in cancer but in its current form cannot be used in economic 
evaluation as it does not incorporate preferences. 
 
Methods and results: We address this gap by estimating a preference-based 
single index for cancer from the EORTC QLQ-C30 for use in economic 
evaluation. Factor analysis, Rasch analysis and other psychometric analyses 
were undertaken on a clinical trial dataset of 655 patients with multiple 
myeloma to derive a health state classification from the QLQ-C30 that is 
amenable to valuation. The resulting health state classification system has 8 
dimensions (physical functioning, role functioning, social functioning, 
emotional functioning, pain, fatigue and sleep disturbance, nausea, and 
constipation and diarrhoea) with 4 or 5 levels each. A valuation study was 
conducted of 350 members of the UK general population using ranking and 
time trade-off. Mean and individual level additive multivariate regression 
models including the episodic random utility model were fitted to the 
valuation data to derive preference weights for the classification system. Mean 
absolute error ranges from 0.046 to 0.054 and models have few 
inconsistencies (0 to 2) in estimated preference weights. 
 
Conclusions: We conclude that it is feasible to derive a preference-based 
measure from the EORTC QLQ-C30 for use in economic evaluation, but this 
work needs to be extended to other countries and replicated across other 
patient groups. 
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Introduction 
 
Generic preference-based measures, such as the EQ-5D [1], HUI3 [2] or SF-6D 
[3] are widely used to calculate quality-adjusted life years (QALYs) [4] for use 
in economic evaluation. The EQ-5D is the most common generic preference-
based measure (PBM) and is currently recommended by NICE [5]. However, 
generic measures of health have been found to be inappropriate or insensitive 
for some medical conditions [6] and for cancer in particular [7]. Furthermore, 
clinicians and researchers often choose to include condition-specific 
measures such as the EORTC QLQ-C30 in trials rather than generic 
preference-based measures because they need measures which are sensitive 
to the effects of interventions across a range of relevant symptoms, side 
effects and aspects of functioning and quality of life. Condition-specific 
measures, such as the EORTC’s core quality of life questionnaire, the QLQ-
C30, have great clinical utility because they summarise a number of symptom 
and domain-specific scales. However, because they are not preference-based, 
they provide a description rather than a valuation of health, and therefore 
cannot be used to estimate QALYs. 
 
There are three ways in which researchers can estimate utilities to produce 
QALYs for a trial where a generic preference-based measure such as the EQ-
5D is unavailable: undertake ‘mapping’; value vignettes that describe the health 
states covered by patients in the trial; or derive a preference-based measure 
from the existing condition-specific measure.  
 
Mapping (also known as ‘cross-walking’ or estimating exchange rates between 
instruments) involves predicting the relationship between the non-
preference-based measure, for example the EORTC QLQ-30, and a generic 
preference-based measure, for example the EQ-5D, using statistical 
association. Mapping by statistical association may be considered less 
arbitrary than using the judgement of experts to map between measures. 
Typically mapping by statistical association uses two datasets; an estimation 
dataset that contains respondents’ self-reported scores for their own health 
using, for example, EORTC QLQ-C30 and EQ-5D and the study dataset that 
contains only EORTC QLQ-C30. A statistical relationship between the EORTC 
QLQ-C30 and EQ-5D is estimated using regression techniques on the 
estimation dataset and the results are applied to the study dataset to obtain 
predicted EQ-5D health state utility values. Mapping is a second best 
alternative to the use of a preference-based measure directly in the study as 
mapped estimates can have large errors, most noticeably when mapping from 
condition-specific measures to generic preference-based measures [8]. 
Mapping requires: 1) a degree of overlap between the descriptive systems of 
both measures, 2) the relationship estimated in the estimation dataset is 
generalisable to the study dataset, and 3) both measures are administered on 
the same population. Yet this means that mapping is valid only if both 
measures are appropriate for the patient population, which is unlikely to be 
the case for generic preference-based measures administered to cancer 
patients [7]. 
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An alternative solution to estimate utilities when generic preference-based 
measures are unavailable or inappropriate is to value a selection of bespoke 
descriptions or vignettes that describe the health states covered by patients in 
the trial. However, patients in the trial experience a variety of different health 
states, and as only a selection will be valued this will not fully take into account 
variation across individuals and across treatments. It is also unlikely that 
identical health states are experienced in trials for different treatments and 
hence vignettes need to be created and valued for each trial which reduces 
comparability across trials and treatments. 
 
It has therefore been argued that a better approach in many cases would be to 
develop a preference-based measure from the condition-specific 
questionnaire specifically designed for that condition [9]. Typically this 
requires reducing the length of the questionnaire to obtain a health state 
classification system that remains responsive and valid for the condition but 
that is amenable to valuation. Preference weights for the health state 
classification are then obtained from a representative sample of the general 
population. 
 
This study applies the methods originally developed in the estimation of a 
generic preference-based measure of health from the SF-36 [3, 10] and 
subsequently used with condition specific measures in urinary incontinence 
[11], asthma [12, 13] and overactive bladder [14, 15]. The study involved three 
stages. First, a health state classification system was derived from the EORTC 
QLQ-C30 that is amenable to valuation using a recognised preference 
elicitation technique. The classification system was derived using 
psychometric analysis, factor analysis and Rasch analysis on a dataset of 
patients with multiple myeloma. Second, a valuation survey was conducted 
asking members of the general population to value a sample of states defined 
by the classification. Third, regression models were estimated on the results 
of the valuation survey to estimate the preference weights to produce a utility 
estimate for every health state defined by the classification system. 
 
EORTC QLQ-C30 
The EORTC QLQ-C30 is one of the most commonly used measures in cancer 
[16] and dominates cancer clinical trials in Europe and Canada. The EORTC 
QLQ-C30 contains 30 questions that cover the most common symptoms of 
cancer (such as pain, fatigue, nausea and vomiting) and various aspects of 
function (including physical, role, social, emotional and cognitive functioning). 
The EORTC QLQ-C30 is summarised using fourteen scales, each representing 
a particular symptom or aspect of function, plus one global quality of life scale 
(based on two global questions). Its validity has been well established for many 
conditions in cancer. 
 
While the EORTC QLQ-C30 has proved to be a useful instrument for 
demonstrating treatment benefits, it cannot be used in economic evaluation in 
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its current form because it does not incorporate preference information. 
While it generates a profile of scores representing a range of symptoms and 
aspects of functioning and a global quality of life score, it does not currently 
generate a single preference-based index of quality of life required for 
economic evaluation using QALYs.  Further, the number of items and scales is 
too large to be amenable to valuation using preference elicitation techniques 
such as time trade off and standard gamble.  
 
EORTC QLQ-C30 multiple myeloma patient dataset 
The dataset used to derive the health state classification system contains data 
on patients newly diagnosed with multiple myeloma. Data were collected in 
VISTA (Velcade as Initial Standard Therapy in Multiple Myeloma: Assessment 
with Melphalan and Prednisone), a phase III randomized open-label trial 
(ClinicalTrials.gov number, NCT00111319) completed in June 2007. Patients 
were asked to complete the EORTC QLQ-C30 at screening visit, day 1 of each 
cycle of treatment (cycles 1-9), end of treatment visit and in post treatment 
phase (every 6 or 8 weeks) until disease progression. The screening phase of 
the dataset (n=655) is used to select items for the health state classification. 
Data at cycle 5 of treatment (n=471) in the trial are then used to validate the 
choice of items for a different time period where responses are likely to have 
changed. 
 
Methods 
 
Methodology used to derive a health state classification from the QLQ-
C30 
The aim was to produce a multidimensional health state classification from the 
EORTC QLQ-C30 that is amenable to valuation by respondents with a 
minimum loss of information and subject to the constraint that responses to 
the original instrument can be unambiguously mapped onto it. This implies 
that the text of the items should be altered as little as possible. The task is 
therefore to determine the dimensions, items and the levels of the EORTC 
QLQ-C30 to be included in the new classification. The methodology outlined 
here uses a combination of Rasch and classical psychometric analysis [15]. 
SPSS version 15 [17] was used for the factor analysis and Rasch Unidimensional 
Measurement Models (RUMM2020) [18] was used for the Rasch analysis.  
 
Dimensional structure 
Multidimensional health state classifications for valuation should have 
structural independence between dimensions to avoid nonsensical states [2]. 
In other words, there must be little correlation between the dimensions in our 
classification system. The large literature on the EORTC QLQ-C30 focuses 
upon its use as a profile measure of health, but here we wish to determine the 
dimensions across all items, ignoring whether these are functions or 
symptoms. 
 
Factor analysis can be used for a set of observed variables to identify 
structurally independent dimensions by highlighting underlying factors that 
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explain patterns of correlation [19]. We applied factor analysis to 27 of the 30 
items of the EORTC QLQ-C30, (excluding global quality of life and financial 
impact items as these are inappropriate for a PBM of health-related quality of 
life) to explore the dimension structure of the EORTC QLQ-C30. The 
dimensions were determined using a varimax component matrix and 
eigenvalues. The extent to which items belong to a single dimension can also 
be examined using Rasch analysis (see below). The results were discussed 
with our team’s clinical expert (GV) to make sure that they made sense 
clinically before making a final decision on the dimensionality of the health 
state classification. 
 
Item selection 
Each dimension of a health state classification system of a preference-based 
measure is usually represented by just one or two items to render the system 
amenable to preference elicitation methods. We used the following 
conventional psychometric criteria to help select items from the QLQ-C30: 
distribution of responses across categories of response (including floor 
effects and ceiling effects), the percentage of missing data, correlation of item 
to dimension, and responsiveness to change over two points in time using the 
standardised response mean (SRM). 
 
A further technique often used [13, 15, 20, 21] to select items is Rasch analysis 
[22]. This is a mathematical technique that converts qualitative (categorical) 
responses to points on a continuous (unmeasured) latent scale using a logit 
model [23]. It can be used to assess whether an item fits the model, the 
severity of health problem being covered by each item, the extent to which 
items have response choices that are appropriately ordered as responders 
can distinguish between the response levels for a given item and whether 
items perform differently between populations (known as differential item 
functioning (DIF)) [15, 20]. Items that fit the Rasch model, cover the full range 
of severity, have ordered response choices and do not suffer from DIF were 
considered as candidates for inclusion in the health state classification. Items 
that did not fit the Rasch model (using criteria that item level Chi-square P-
value<0.01) were removed; all other items were retained and the Rasch 
analysis was re-estimated. We used the following criteria to assess the Rasch 
model for each dimension: item-trait interaction (whether data fitted the 
Rasch model for groups of respondents with similar underlying health); 
person separation index (PSI) (whether the Rasch model could discriminate 
between responders); item fit and person fit residuals (the divergence 
between expected and observed responses per respondent); and item range 
and spread at logit zero (whether items covered a wide range of severity). 
 
The final selection of dimensions, items and levels for the health state 
classification was based on what appeared to perform best using the 
psychometric tests and Rasch analysis and at the same time ensuring that 
health states made clinical sense and were amenable to valuation by 
respondents. The process involved judgment by our clinical expert (GV) and 
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consideration of other factors such as wording of the health state 
classification system. 
 
Valuation study to obtain preferences for the health state classification 
The second stage of the research was to obtain valuations of states defined by 
the health state classification system. Key methodological issues were the 
choice of technique for eliciting preferences, the sample of states valued, 
sampling of respondents and overall size of sample.  
 
The valuation technique used to value health states was Time Trade-off (TTO). 
States were sampled using an orthogonal array in order to enable the 
estimation of an additive model for the preference weights. Use of an 
orthogonal array to sample states is common when dimensions are 
independent. SPSS version 15 was used to produce a sample of 81 states using 
orthogonal array and this was supplemented by 4 additional states. We chose 
to value 85 states in order to enable each respondent to value the worst state, 
an equal number of responses per state, and an equal number of states to be 
valued per respondent.  
 
At the interview, respondents read the descriptive system and self-completed 
the system for their own health. The EORTC QLQ-C30 does not mention 
cancer in its descriptive system and therefore respondents were not aware 
that the health states were used to describe the health-related quality of life 
of cancer patients. Respondents were asked to rank 8 states alongside ‘full 
health’ and ‘dead’ to help familiarize them with the states. Respondents then 
valued the same 8 states using the Measurement and Valuation of Health 
(MVH) study version of TTO that involves the use of a visual prop designed by 
the MVH group (University of York) [24]. Respondents were initially taken 
through a hypothetical TTO to help them understand the task. For each health 
state respondents were first asked whether they would prefer the given 
health state for 10 years after which they will die, or to die immediately. For 
health states considered better than being dead (BTD), respondents were 
asked to choose between (a) health state h for w years, after which they will 
die, or (b) full health for z years ( wz ≤ ), after which they will die.  While w is 
fixed at 10 years, years in full health, z, is varied to determine the point where 
respondents are indifferent between the two options. For health states 
considered worse than being dead (WTD) respondents were asked to choose 
between (a) health state h for w years followed by full health for z years after 
which they will die, or (b) immediate death. Both years in optimal health, z, 
and years in health state, w=10-z, are varied to determine the point where 
respondents are indifferent between the two options. After the collection of 
trade-off responses (w, z), respondents were asked a number of background 
questions covering demographic and socio-economic characteristics. 
 
A representative sample of the general population was interviewed in their 
own homes by trained and experienced interviewers who had worked on 
numerous previous valuation surveys, such as the HUI2 [25] and OAB-5D [14]. 
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The valuation data 
Respondents were from geographical areas in the North of England including 
urban and rural areas with a mix of socio-economic characteristics. There 
were 350 successfully conducted interviews, a response rate of 40.3% for 
suitable respondents answering their door at time of interview. Six 
respondents were excluded from the analysis; three were excluded for valuing 
all states as identical and less than one; two respondents were excluded for 
valuing the worst possible health state higher than every other state; one 
respondent was excluded for valuing all states as worse than dead. All other 
responses were used in the analysis reported here. The remaining 344 
respondents had a health state completion rate of 98.5% in the TTO tasks. 
Characteristics of the included respondents are compared to the general 
population in South Yorkshire and England (Table 1). The valuation sample 
contained a higher proportion of people aged 41-65, retired people, females 
and people in poorer health than in the population at large. 
 
Modelling to obtain preference weights for the health state 
classification 
The TTO responses (z,w) were analysed using a range of different 
specifications. The standard specification is based on the approach first used 
for the UK EQ-5D preference weights [24]: 
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where i=1,2 …n represents individual health states and j=1,2…m represents 
respondents. The dependent variable sijy  is disvalue for health state i valued by 
respondent j and δλX  is a vector of dummy explanatory variables for each level 
λ of dimension δ  of the health state classification. Level λ = 1 acts as a baseline 
for each dimension. 
 
The second specification is the episodic random utility model (ERUM), where 
the value of the health state depends on its duration, ijw : 
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In order to produce error terms on the same scale as the standard 
specification in equation (1), both ijz and ijw are divided by 10 before 
estimation. 
 
The standard approach transforms WTD TTO responses to bound value 
estimates at -1. This has been criticised, as there is little empirical evidence for 
why values should be bound at -1 and arguably the transformed responses 
cannot be interpreted as being measured on the same utility scale as states 
BTD [26]. The ERUM model was developed to deal with this criticism by 
changing the way TTO responses are modelled. Under the ERUM, WTD TTO 
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responses are not transformed and are therefore modelled in a way that is 
consistent with BTD responses [27].  
 
Each model was estimated using ordinary least squares (OLS) estimation with 
clusters at the respondent-level, which assumes that responses may be 
correlated within respondent and are independent between respondents. 
Random and fixed effects were estimated in the standard approach to take 
into account individual differences in values (Brazier et al, 2002). For the 
random and fixed effects model the error term, ijε  is subdivided as follows: 
 
ijjij eu +=ε       (3) 
 
where uj is individual random effect and eij is the random error term for the 
ith health state valuation of the jth individual. Maximum likelihood estimation 
was used for the random effects estimation. 
 
Instead of examining individual responses, the dependent variable under the 
standard specification, sijy , may be condensed into mean estimates, iy , for 
each ith state. Using the 85 mean estimates, the standard model (equation 1) 
can also be estimated via OLS: 
ii fy εδ += )( βX λ      (4) 
The use of mean estimates diminishes the effects of outliers in the distribution 
of sijy . The impact of adding interaction terms and socio-demographic 
variables is explored for all models. 
 
Several alternative criteria to indicate model performance are reported. The 
difference between actual and predicted values is assessed using mean 
absolute error (MAE) calculated at the health state level. MAE is an indicator of 
how large the prediction errors are and reporting the number of health states 
valued with errors greater than 5% and 10% indicates whether the errors are 
of a minimal important difference. Inconsistencies in parameter estimates for 
adjacent levels of an item were noted as these indicated that worsening health 
did not lead to a lower utility value. Models in which these inconsistencies 
were removed by merging levels were also estimated. The number of main 
effects with insignificant coefficients is also reported. Performance of all 
regression models is reported using inconsistencies, significant coefficients, 
mean absolute error of health state predictions and MAE greater than 5% and 
10% and by examining plots of actual and predicted health state values. 
 
Results 
 
Health state classification 
Step 1: Instrument dimensionality 
A four factor model on all 27 items accounted for 58.7% of the variance. Items 
were divided into the four factors according to their ‘loadings’, the correlation 
between the item and the factor. All items loaded >0.35 on a factor, but some 
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items cross loaded. Factor 1 contained the majority of items (14), covering 
physical functioning, role functioning, social functioning, pain and items ‘need a 
rest’, ‘felt weak’ and ‘difficulty concentrating’. Factor 2 contained all items 
covering emotional functioning plus ‘trouble sleeping’. Factor 3 contained all 
items covering eating and digestion and factor 4 contained items ‘short of 
breath’, ‘were you tired’ and ‘difficulty remembering’. Items loading into 
factors 2 and 3 were conceptually clear and in accordance with the grouping 
of the original EORTC instrument. Items loading into factors 1 and 4 (17 items), 
on the other hand, covered a large range of concepts and further factor 
analysis was done on these items to determine whether further differentiation 
was possible. The additional item ‘trouble sleeping’ was added (18 items in 
total) over a concern that the initial factor analysis captured some causality 
rather than correlation. 
 
A four factor model on the 18 items explained 67.6% of the variance. All items 
loaded >0.4 on a factor, but some items cross loaded (difference between 
cross loadings <0.2). Cross loading items were included in the factor that was 
clinically meaningful.  The four factors were: physical functioning, role 
functioning and pain; social functioning; fatigue, trouble sleeping and short of 
breath; cognitive functioning (principal-component rotated factor loadings are 
available from authors on request). 
 
Table 2 shows the potential items categorised according to the dimensions for 
consideration for the measure amenable to valuation. Overall the 27 items can 
be divided into 6 factors or dimensions: (1) physical functioning, role 
functioning and pain, (2) social functioning, (3) emotional functioning, (4) 
digestion, (5) fatigue, trouble sleeping and shortness of breath and (6) 
cognitive functioning. After consultation with our clinical specialist (GV), 
cognitive functioning (items 20 and 25) and shortness of breath (item 8) were 
excluded from the PBM on the grounds that they are neither a symptom nor 
side effect of treatment for multiple myeloma, leaving 24 items remaining. The 
remaining five dimensions are used for the following analysis to determine the 
PBM, where items were fitted to Rasch models for each of the five dimensions. 
 
Step 2: Selecting items by dimension 
Table 2 presents psychometric analysis and goodness of fit for the Rasch 
models for each dimension. 
 
Item-level ordering and differential item functioning 
Only item 15 (digestion dimension) was disordered and for this item ‘a little’, 
‘quite a bit’ and ‘very much’ were collapsed into one level prior to proceeding 
with further Rasch modelling. Four items demonstrated differential item 
functioning by sex and were split according to sex: items 1 and 3 (physical 
functioning, role functioning and pain dimension), item 15 (digestion) and item 
22 (emotional functioning). Item 21 (emotional functioning) demonstrated 
differential item functioning by age and was split according to age. This 
indicated that these items were not ideal for the health state classification. 
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Rasch model goodness of fit 
Three items demonstrated poor item fit (Chi-square P-value<0.01) and were 
excluded from subsequent Rasch models estimated for each dimension: item 
6 (physical functioning, role functioning and pain dimension), item 14 
(digestion), item 11 (fatigue). 
 
Physical functioning, role functioning and pain 
This dimension covers three separate attributes of quality of life: physical 
functioning, role functioning and pain. Each item covers only one attribute and 
it is unlikely that an item on physical functioning, for example, will capture or 
reflect role functioning or pain. In order to accurately represent the entire 
dimension, and in accordance with the EORTC QLQ-C30 scaling and with 
clinical opinion, we decided that a minimum of one item each for physical 
functioning, role functioning and pain was required. 
 
Out of the 5 items that capture physical functioning, items 4 and 5 did not 
capture the full range of severity but had the highest SRM suggesting better 
responsiveness and ability to capture severe health problems, though in all 
cases they were low according to Cohen’s criteria [28]. Item 2 overall 
performed well with relatively high item fit but had floor effects, relatively low 
SRM and limited range of severity. Figure 1 shows the item map for all items in 
this dimension, reporting three thresholds between response categories ‘not 
at all’ and ‘a little’, ‘a little’ and ‘quite a bit’, and ‘quite a bit’ and ‘very much’. No 
item captured the full severity range in terms of coverage as items 3, 4 and 5 
captured severe health whereas items 1 and 2 captured less severe health. 
Given that none on the items were ideal, items 2 and 3 were chosen in order 
to cover the full severity range and there is a coherence since both measure 
trouble walking. Items 2 and 3 were merged to a five level item in the health 
state classification, with levels 1 to 4 taken directly from item 2 (no/a 
little/quite a bit/very much trouble taking a long walk) and level 5 (very much 
trouble taking a short walk outside of the house) taken from level 4 of item 3. 
 
Of the two role functioning items, item 7 had ceiling effects, but also had good 
Rasch model item fit and relatively good item range (Figure 1). Item 6 
performed similarly to item 7 for the psychometric analysis, but had poor 
Rasch model item fit. Therefore item 7 was selected for the health state 
classification to represent role functioning. 
 
Items 9 and 19 capture pain. Item 9 had a large severity range, but poor item 
fit, very high item fit residual and low item level p-value suggesting the item 
contributes poorly to the dimension. Item 19 had a more limited range and 
more evidence of ceiling effects but better item fit. Item 19 was chosen due to 
better item fit and due to its wording, since it measures the extent to which 
pain interferes with daily activities rather than the existence of pain per se, 
which is likely to be more important to respondents. 
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Social functioning 
Of the two social functioning items, item 26 had a slightly higher degree of 
ceiling effects, higher item fit residual and lower p-value. Further, it may not be 
applicable to all respondents as it captures whether physical condition or 
medical treatment interferes with family life. Item 27 was chosen as it 
performs marginally better psychometrically and is arguably applicable to a 
higher number of respondents as it measures interference with social 
activities. 
 
Emotional functioning 
Items 21 and 22 suffered from DIF. Items 23 and 24 performed similarly across 
all criteria. Item 23 had a larger severity range than item 24, but also had a 
higher item fit residual, suggesting greater divergence between expected and 
observed responses. Item 24 was chosen as it overall performs best, had a 
higher SRM and was felt to be more clinically relevant to patients with cancer. 
 
Digestion 
None of the digestion items performed well in psychometric or Rasch analysis. 
Despite this, they were included in the health state classification as it was felt 
that they were clinically important for patients with multiple myeloma. These 
items capture multiple symptoms of digestion-related problems: lack of 
appetite, nausea, vomiting, constipation and diarrhoea. Lack of appetite, 
nausea and vomiting (items 13, 14, 15) are all closely related symptoms, and 
constipation and diarrhoea (items 16 and 17) are bowel symptoms, suggesting 
the items can be separated into two attributes. Item 13 was the only item from 
appetite, nausea and vomiting that did not suffer from DIF, item level 
disordering or poor item fit. However, this item performed poorly in the Rasch 
model with small coverage at logit zero and high item fit residuals. After 
consultation amongst our research team, including our clinical specialist, it 
was decided that item 13, which captures lack of appetite, would not be 
chosen because it may be thought to be a desirable (positive) symptom by 
some people and may be a symptom due to the age of the population rather 
than the condition. Therefore, despite suffering from problems in the Rasch 
model items 14 and 15 were considered as it was felt to be important to 
capture appetite, nausea or vomiting in the health state classification. Both 
items suffer from large ceiling effects and have low SRM, with item 14 
performing marginally better. Therefore item 14 (nausea) was chosen for the 
health state classification. 
 
Items 16 and 17 on constipation and diarrhoea perform similarly, both suffering 
from extreme ceiling effects, small spread at logit zero and high residuals. It 
was decided to combine these items as they are both bowel symptoms where 
respondents rarely suffer from both during a weekly period. The items were 
combined such that level 1 of the merged item captures no bowel 
(constipation or diarrhoea) problems, levels 2, 3 and 4 capture ‘a little’ ‘quite a 
bit’ and ‘very much’ constipation and/or diarrhoea. 
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Fatigue and sleep disturbance 
Items 10, 12 and 18 performed similarly in the Rasch and psychometric 
analyses, with large severity range and no large ceiling or floor effects. 
However, item 10 had a relatively high item fit residual and item 12 has a low 
item p-value, indicating it does not contribute well to the dimension in Rasch 
models. Item 18 performed marginally better, with a relatively high p-value, low 
residual, large coverage at logit zero and large range, and so was selected for 
the health state classification. 
 
Health state classification 
The classification system has 8 dimensions (physical functioning, role 
functioning, pain, emotional functioning, social functioning, fatigue and sleep 
disturbance, nausea, constipation and diarrhoea) made up of 10 items. Table 4 
summarises the items chosen from the EORTC QLQ-C30 for each dimension 
of the health state classification. Table 5 presents the final health state 
classification system of dimensions and their levels. A health state is made up 
of 8 sentences and hence has an 8 digit identifier, from best state 11111111 to 
worst state 54444444. This system generates a total of 81,920 health states. 
 
Valuation survey 
Mean TTO values varied from 0.95 for best state to 0.13 for worst state 
(available from authors on request), which suggests that on average all states 
were valued as better than being dead. Of the total 2710 TTO observations, 514 
observations (19%) were equal to 1 (equivalent in value to full health) and 271 
(10%) were less than or equal to 0 (valued as the same or worse than being 
dead). 
 
Modelling health state values 
Table 6 presents the preference weights estimated using a variety of 
regression models. All coefficients have the expected sign (i.e., level 1 on each 
dimension is the reference point and higher levels increase TTO disvalue), 
their size is consistent with the severity scale in all but two cases (i.e., higher 
levels have larger coefficients and an increasing increment on TTO disvalue 
except physical functioning levels 4 and 5 and nausea levels 2 and 3) and the 
majority of coefficients are statistically significant. Models (1), (2), (4) and (5) 
are based on the standard specification outlined in equations (1) and (4), 
model (3) uses the ERUM specification in equation (2). Models (1) and (3) are 
individual level models estimated using OLS, model (2) is a random effects 
model estimated using maximum likelihood. The results of the Hausman test 
confirmed that a fixed effects model would render similar estimates at 
reduced efficiency. Models (4) and (5) are mean level models. Model (5) is a 
consistent version of model (4) where adjacent inconsistent levels are merged 
into a common dummy variable. 
Mean absolute error was similar between models, ranging from 0.046 to 
0.054. The number of health states with errors greater than 5% ranges from 
33 to 41 and errors greater than 10% ranges from 6 to 13. Models including 
interaction effects and socio-demographic were estimated (available from the 
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authors by request) but predictive ability, inconsistencies and significant 
coefficients for the main effects variables were not improved. 
 
 
Discussion 
 
We have estimated a preference-based measure for the EORTC QLQ-C30 
using methodology first applied in the development of the SF-6D from the SF-
36 [3] and a number of condition specific measures. The derived preference-
based measure including 8 dimensions, the EORTC-8D, was constructed using 
psychometric analysis (including Rasch) to ensure that chosen items 
appropriately reflected their dimension and that each dimension covered a 
wide range of severity. A sample of states was valued using time trade-off and 
then modelled using a variety of specifications. The estimated preference 
weights enable utility scores to be generated directly from EORTC QLQ-C30 
datasets. 
 
An important concern is that often condition-specific measures fail to capture 
co-morbidities and side-effects of treatments, and hence are not strictly 
comparable to generic measures when used to estimate QALYs for resource 
allocation. One way to enhance comparability across measures is for all 
measures to use the same methodology to derive values [6]. Our valuation 
study followed the methodology used in the development of generic 
measures: we implemented the protocol used to derive the UK EQ-5D 
preference weights [24]; used common anchors of 1 for full health and zero for 
dead; and interviews were conducted using a sample of the general 
population. Furthermore, the EORTC-8D descriptive system captures a wide 
range of dimensions including generic dimensions such as physical functioning 
and role functioning, as well as more condition-specific symptoms such as 
nausea, constipation and diarrhoea. Therefore the descriptive system is likely 
to capture overall health-related quality of life including both comorbidities 
and side-effects.  An area of future research will be to compare this cancer-
specific measure to generic measures in terms of sensitivity and validity. 
 
A general concern regarding the development of PBMs from existing 
questionnaires is that the classification system is strongly influenced by the 
specific patient dataset used to develop the classification. While the patient 
dataset is international, the valuation study used here is a UK dataset and 
hence the EORTC-8D classification and preference weights presented here 
might be more appropriate for UK trials. The health state classification was 
developed using data in newly diagnosed multiple myeloma patients. Further 
testing of the classification will be undertaken across datasets of cancer 
patients with different types of cancers. This study forms part of a wider 
cross-country study that will examine the use of preference-based measures 
from the EORTC QLQ-C30 on a variety of countries and different patient 
groups. 
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Given that the health state classification measures cancer, it is somewhat 
surprising that all states have a positive mean TTO value and hence at the 
aggregate level all states are valued as being better than being dead. This is in 
contrast to other valuation studies such as the UK EQ-5D valuation study 
where 38% (16/42) of health states valued were on average valued as being 
worse than dead (with mean TTO below zero). One hypothesis is that 
respondents would view the states differently if cancer was included in the 
health state description, and this is a topic for future research. 
 
The preference weights should have no inconsistencies; health state values 
should always decrease as health states become more severe. Models based 
on the standard specification produced inconsistencies for physical 
functioning levels 4 and 5. This may have been due to the merging of items in 
the EORTC QLQ-C30 to form this dimension. Models (1) and (3) also produce 
inconsistencies for nausea levels 2 and 3. Model (5) removes inconsistencies 
by merging variables. In comparison, models (3) and (5) perform best overall 
according to the criteria of predictive ability, inconsistencies and significant 
coefficients, with model (3) performing better using all criteria. Model (5) has 
a predicted range of utilities from 1 to 0.199 whereas model (3) has a 
predicted range of 1 to 0.291, meaning that the worst state defined by the 
classification has a much lower value using preference weights estimated 
using model (5). Deciding upon the preferred model comes down to a choice 
between the mean model (5) with no inconsistencies, as chosen both in the 
valuation of the SF-6D [29] and the overactive-bladder-specific measure [14], 
or the recently developed ERUM specification. Although model (5) is in 
accordance with the recommended value set of many similar measures, the 
ERUM model (3) is here the preferred model as it more appropriately deals 
with TTO values for SWD and performs best. 
 
The EORTC-8D was developed out of a concern that generic measures were 
not appropriate to measure the quality of life of cancer patients [7]. The 
EORTC-8D enables QALYs to be directly estimated using the EORTC QLQ-C30, 
a questionnaire typically included in cancer trials, rather than the use of 
generic measures that are less appropriate [7] or mapping to generic 
measures that is both less appropriate and increases error around utility 
estimates. It is hoped that this measure will provide appropriate and useful 
information for cost per QALY analysis undertaken in cancer trials. 
 
References 
 
1.  Brooks R 1996. 
EuroQol Group. EuroQol: the current state of play. 
Health Policy 3:53-72. 
 
2.  Feeny D, Furlong W, Torrance GW, Goldsmith CH, Zhu Z, DePauw S, Denton 
M, Boyle M (2002). 
Multiattribute and single attribute utility functions for the Health Utilities Index 
Mark 3 system. 
Deriving a preference-based measure for cancer 
 18 
Medical Care 40:113-28. 
 
3.  Brazier J, Roberts J, Deverill M (2002). 
The estimation of a preference-based single index measure for health from 
the SF-36. 
Journal of Health Economics 21(2):271-92. 
 
4.  Drummond M (1994). 
Economic evaluation alongside clinical trials. 
London: Department of Health. 
 
5.  NICE (2008). 
Guide to the methods of technology appraisal. 
http://www.nice.org.uk/aboutnice/howwework/devnicetech/technologyappra
isalprocessguides/guidetothemethodsoftechnologyappraisal.jsp 
London. 
 
6.  Brazier JE, Ratcliffe J, Tsuchiya A, Solomon J (2007). 
Measuring and valuing health for economic evaluation.  
Oxford: Oxford University Press. 
 
7.  Garau M, Shah K, Towse A, Wang Q, Drummond M, Mason A (2009). 
Assessment and appraisal of oncology medicines: does NICE’s approach 
include all relevant elements? What can be learnt from international HTA 
experiences? 
Report for the Pharmaceutical Oncology Initiative (POI) 
 
8.  Brazier J, Yang Y, Tsuchiya A, Rowen D (2009). 
A review of studies mapping (or cross walking) from non-preference based 
measures of health to generic preference-based measures. 
European Journal of Health Economics, in press. 
 
9.  Brazier JE, Dixon S (1995). 
The use of condition specific outcome measures in economic appraisal. 
Health Economics 4:255-64. 
 
10.  Brazier JE, Harper R, Thomas K, Jones N, Underwood T (1998). 
Deriving a preference based single index measure from the SF-36. 
Journal of Clinical Epidemiology 51(11):1115-29. 
 
11.  Brazier JE, Czoski-Murray C, Roberts J, Brown M, Symonds T, Kelleher C 
(2008). Estimation of a preference-based index from a condition specific 
measure: the King’s Health Questionnaire. 
Medical Decision Making 28(1):113-26. 
 
12.  Yang Y, Tsuchiya A, Brazier J, Young T (2007). 
Estimating a preference-based single index from the Asthma Quality of Life 
Questionnaire (AQLQ). 
Deriving a preference-based measure for cancer 
 19 
Health Economics and Decision Sciences Discussion Paper 07/02. 
http://www.shef.ac.uk/scharr/sections/heds/discussion.html 
 
13.  Young T, Yang Y, Brazier J, Tsuchiya A (2007). 
The use of Rasch analysis as a tool in the construction of a preference based 
measure: the case of AQLQ. 
Health Economics and Decision Sciences Discussion Paper 07/01. 
http://www.shef.ac.uk/scharr/sections/heds/discussion.html 
 
14.  Yang Y, Brazier JE, Tsuchiya A, Coyne K (2009). 
Estimating a preference-based index from the Overactive Bladder 
questionnaire. 
Value in Health 12(1):159-66. 
 
15.  Young T, Yang Y, Brazier J, Tsuchiya A, Coyne K (2009). 
The first stage of developing preference-based measures: constructing a 
health-state classification using Rasch analysis.  
Quality of Life Research 18:253-65. 
 
16.  Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, et al (1993). 
The European Organization for Research and Treatment of Cancer QLQ-C30: a 
quality-of-life instrument for use in international clinical trials in oncology. 
Journal of the National Cancer Institute 85(5):365-76. 
 
17.  SPSS for Windows. Release. 14.0.1. 2005. Chicago: SPSS Inc. 2005  
 
18.  Rasch Unidimensional Measurement Models (RUMM) 2020. RUMM 
Laboratory Pty Ltd 1997-2004. 
 
19.  Chatfield C, Collins AJ (1980). 
Introduction to Multivariate Analysis. 
Chapman and Hall. 
 
20.  Young T, Rowen D, Brazier J, Norquist J, Ambegaonkar B, Sazonov V 
(2009).  
Developing preference-based health measures: using Rasch analysis to 
generate health state values. 
Health Economics and Decision Sciences Discussion Paper, forthcoming. 
 
21.  Mavranezouli I, Brazier JE, Young TA, Barkham M (2009). 
Using Rasch analysis to form plausible health states amenable to valuation: the 
development of CORE-5D Utility from CORE-OM in order to elicit preferences 
for common mental health problems. 
Health Economics and Decision Sciences Discussion Paper 09/09. 
http://www.shef.ac.uk/scharr/sections/heds/discussion.html 
 
22.  Rasch G (1960). 
Probabilistic models for some intelligence and attainment tests. 
Deriving a preference-based measure for cancer 
 20 
Chicago: University of Chicago Press. Reprinted 1980. 
 
23.  Tesio L (2003). 
Measuring behaviours and perceptions: Rasch analysis as a tool for 
rehabilitation research. 
Journal of Rehabilitation Medicine 35(3):105-15. 
 
24.  Dolan P (1997). 
Modelling valuations for EuroQol health states. 
Medical Care 35(11):1095-108. 
25.  McCabe C, Stevens K, Roberts J, Brazier J (2005). 
Health state values for the HUI 2 descriptive system: Results from a UK survey. 
Health Economics 14:231-44. 
 
26.  Patrick DL, Starks HE, Cain KC, Uhlmann RF, Pearlman RA (1994). 
Measuring  preferences for health states worse than death. 
Medical Decision Making 14:9-18. 
 
27.  Craig BM, Busschbach JJV (2009). 
The episodic random utility model unifies worse than death and better than 
death TTO responses in health state valuation. 
Population Health Metrics 7(3):1-10. 
 
28.  Cohen J (1978). 
Statistical power analysis for the behavioural sciences. 
New York: Academic Press. 
 
29.  Brazier J, Roberts J (2004). 
The estimation of a preference-based index from the SF-12. 
Medical Care 42:851-9. 
 
30.  Kind P, Hardman G, Macran S (1999). 
UK population norms for EQ-5D. 
Centre for Health Economics Discussion Paper Series, University of York. 
 
31.  Drummond MF, O’Brien BJ, Stoddart GL, Torrance GW (1997). 
Methods for the economic evaluation of health care programmes. 
Oxford: Oxford Medical Publications. 
 
32.  Brazier J, Yang Y, Tsuchiya A, Rowen D (2009). 
A review of studies mapping (or cross walking) from non-preference based 
measures of health to generic preference-based measures. 
European Journal of Health Economics (in press). 
 
33.  NICE (2004). 
Guide to the methods of technology appraisal. 
(http://www.nice.org.uk/pdf/TAP_Methods.pdf) 
Deriving a preference-based measure for cancer 
 21 
 
34.  Stevens K, Brazier J, McKenna S, Doward L, Cork M (2005). 
The development of a preference-based measure of health in children with 
atopic dermatitis. 
British Journal of Dermatology 153:372-7. 
 
Deriving a preference-based measure for cancer 
 22 
Figure captions 
 
Figure 1: Item map for physical functioning, role functioning and pain 
dimension
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Table 1: Characteristics of respondents 
 Included respondents 
(n=344)1 
South Yorkshire2 England2 
Mean age (s.d.) 47.8 (18.5) NA NA 
Age distribution 
       18-40 
       41-65 
       Over 65 
 
38.6% 
42.7% 
17.2% 
 
41.2% 
39.1% 
19.7% 
 
41.6% 
39.1% 
19.3% 
Female 61.9% 51.2% 51.3% 
Married/Partner 57.0% NA NA 
Employed or self-employed 43.6% 56.1% 60.9% 
Unemployed 0.6% 4.1% 3.4% 
Long-term sick 6.4% 7.7% 5.3% 
Full-time student 7.3% 7.5% 7.3% 
Retired 24.7% 14.4% 13.5% 
Own home outright or with a 
mortgage 
69.2% 64.0% 68.7% 
Renting property 29.9% 36.0% 31.3% 
Secondary school is highest 
level of education 
41% NA NA 
EQ-5D score (s.d.) 0.82 (0.26) NA 0.86 (0.23) 
TTO completion rate 98.5%   
 
 
1 Six respondents were excluded; three for valuing all states as identical and less than 
1; two for valuing the worst possible state higher than every other state; one for 
valuing all states as worse than dead. 
2 Statistics for South Yorkshire Health Authority and for England in the Census 2001. 
Questions used in this study and the census are not identical. The census includes 
persons aged 16 and above whereas this study only surveys persons aged 18 and 
above. Age distribution is here reported as the percentage of all adults aged 18 and 
over. 
3 Interviews conducted in the Measurement and Valuation of Health (MVH) study in 
1993 [30].
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Table 2: Summary of psychometric and Rasch analysis used to select items per dimension 
  Psychometric analysis Rasch analysis 
Items Item summary % 
response 
at floor 
(very 
much) 
% 
response 
at ceiling 
(not at all) 
% 
missing 
data 
Correlation 
with domain 
score 
SRM Item range Residual Item level 
chi-sq P-
value 
Spread at 
logit zero 
Disor-
dered 
DIF 
charac-
teristic 
Poorly fitting item 
in Rasch model 
(chi-sq P-value < 
0.01) 
Physical and role functioning and pain 
1 Trouble doing 
strenuous activities 
28.5 14.4 0.6 -0.869 -0.206      Sex   
2 Trouble taking a 
long walk 
26.9 16.9 1.1 -0.896 -0.195 -2.576 to 
0.516 
-1.540 0.385 0.93 to 
0.37 
   
3 Trouble taking a 
short walk 
8.1 46.7 1.7 -0.844 -0.235      Sex  
4 Need to stay in bed 
or a chair during the 
day 
9.3 36 1.4 -0.788 -0.289 -1.158 to 
2.385 
0.874 0.120 0.76 to 
0.08 
   
5 Need help with 
eating, dressing, 
washing or using the 
toilet 
4.1 72.8 0.6 -0.575 -0.313 1.220 to 
2.584 
-0.678 0.083 0.23 to 
0.07 
   
6 Limited in doing your 
work or daily 
activities 
18.5 25.8 1.5 -0.953 -0.259       Yes 
7 Limited in pursuing 
hobbies or other 
leisure time activities 
17.9 30.1 1.2 -0.954 -0.237 -1.526 to -
1.192 
-0.629 0.600 0.82 to 
0.23 
   
9 Pain 20 20.2 0.9 0.926 -0.499 -2.176 to 
1.004 
4.685 0.075 0.90 to 
0.27 
   
19 Pain interfered with 
daily activities 
20 30.4 0.5 0.936 -0.432 -1.427 to 
0.987 
-0.844 0.138 0.81 to 
0.27 
   
Social functioning 
26 Physical condition or 
medical treatment 
interfered with family 
life 
8.7 49.2 0.8 -0.899 -0.085 -1.247 to 
2.013 
1.146 0.175 0.78 to 
0.12 
   
27 Physical condition or 
medical treatment 
interfered with social 
life 
12.8 41.8 0.6 -0.942 -0.090 -1.869 to 
1.144 
0.555 0.345 0.87 to 
0.24 
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  Psychometric analysis Rasch analysis 
Items Item summary % 
response 
at floor 
(very 
much) 
% 
response 
at ceiling 
(not at all) 
% 
missing 
data 
Correlation 
with domain 
score 
SRM Item range Residual Item level 
chi-sq P-
value 
Spread at 
logit zero 
Disor-
dered 
DIF 
charac-
teristic 
Poorly fitting item 
in Rasch model 
(chi-sq P-value < 
0.01) 
Emotional functioning 
21 Feel tense 6.6 37.7 0.9 -0.834 -0.264      Age  
22 Worried 12.8 26.0 0.2 -0.860 -0.477      Sex  
23 Feel irritable 4.3 44.3 0.5 -0.776 -0.223 -1.546 to 
2.740 
3.912 0.442 0.82 to 
0.06 
   
24 Feel depressed 7.8 41.5 0.8 -0.834 -0.330 -1.696 to 
2.017 
-0.742 0.232 0.85 to 
0.12 
   
Digestion 
13 Lacked appetite 8.9 48.9 0.5 No domain -0.348 -1.349 to -
0.314 
-2.244 0.027 0.79 to 
0.58 
   
14 Felt nauseated 2.4 73.9 0.3 No domain -0.124       Yes 
15 Vomited 1.2 87.9 0.3 No domain -0.046     Yes Sex  
16 Constipated 7.3 52.7 0.5 No domain -0.225 -1.258 to -
0.449 
-1.220 0.231 0.78 to 
0.61 
   
17 Had diarrhoea 0.8 79.5 0.9 No domain 0.058 -0.081 to 
1.083 
1.029 0.027 0.52 to 
0.25 
   
Fatigue and trouble sleeping 
10 Needed to rest 15.9 14 1.4 No domain -0.326 -3.113 to 
2.212 
1.409 0.881 0.96 to 
0.10 
   
11 Trouble sleeping 10.1 41.4 0.2 No domain -0.276       Yes 
12 Felt weak 12.7 22.6 0.6 No domain -0.296 -2.155 to 
2.641 
-0.433 0.043 0.90 to 
0.07 
   
18 Tired 12.8 15.9 0.3 No domain -0.245 -2.933 to 
2.805 
-0.727 0.540 0.95 to 
0.06 
   
 
Note: DIF by sex is split male/female and DIF by age is split <65/65+. 
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Table 3: Goodness of fit for the Rasch model for each dimension 
 Item-trait interaction 
Dimension Chi-sq 
(degrees of 
freedom) 
P-value Item fit 
(SD) 
Person fit 
(SD) 
Person 
separation 
index 
Physical and 
role functioning 
and pain 
121.36 (88) 0.01 -0.58(2.12) -0.32(1.02) 0.90 
Social 
functioning 
10.82 (8) 0.21 0.85(0.42) -0.44(0.80) 0.79 
Emotional 
functioning 
65.34 (54) 0.14 -0.18(2.14) -0.35(0.96) 0.85 
Digestion 72.08 (35) 0.00 -0.67(1.20) -0.30(0.75) 0.47 
Fatigue and 
trouble sleeping 
22.05 (20) 0.34 0.08(1.16) -0.65(1.27) 0.83 
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Table 4: Summary of EORTC QLQ-30 items included in the EORTC-8D 
descriptive system 
EORTC-8D dimension EORTC QLQ-
C30 items 
Question 
Physical functioning 2 Trouble taking a long walk 
3 Extra level added from ‘trouble taking a 
short walk’ 
Role functioning 7 Limited in pursuing hobbies or other leisure 
time activities 
Pain 19 Pain interfered with daily activities 
Social functioning 27 Physical condition or medical treatment 
interfered with social life 
Emotional functioning 24 Felt depressed 
Nausea 14 Felt nauseated 
Constipation and 
diarrhoea 
16 Constipated 
17 Diarrhoea 
Fatigue and trouble 
sleeping 
18 Tired 
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Table 5: EORTC-8D descriptive system 
During the past week: 
 
Physical functioning 
You had no trouble taking a long walk 
You had a little trouble taking a long walk 
You had quite a bit of trouble taking a long walk 
You had very much trouble taking a long walk  
You had very much trouble taking a short walk outside of the house  
 
Role functioning 
You were not limited in pursuing your hobbies or other leisure time activities 
You were limited a little in pursuing your hobbies or other leisure time activities 
You were limited quite a bit in pursuing your hobbies or other leisure time activities 
You were limited very much in pursuing your hobbies or other leisure time activities 
 
Pain 
Pain did not interfere with your daily activities 
Pain interfered a little with your daily activities  
Pain interfered quite a bit with your daily activities  
Pain interfered very much with your daily activities  
 
Emotional functioning 
You did not feel depressed 
You felt a little depressed 
You felt quite a bit depressed  
You felt depressed very much 
 
Social functioning 
Your physical condition or medical treatment did not interfere with your social activities 
Your physical condition or medical treatment interfered a little with your social activities  
Your physical condition or medical treatment interfered quite a bit with your social activities  
Your physical condition or medical treatment interfered very much with your social activities  
 
Fatigue and sleep disturbance 
You were not tired 
You were a little tired 
You were quite a bit tired  
You were tired very much 
 
Nausea 
You did not feel nauseated  
You felt a little nauseated 
You felt nauseated quite a bit 
You felt nauseated very much 
 
Constipation and diarrhoea 
You were not constipated and did not have diarrhoea 
You were constipated and/or had diarrhoea a little 
You were constipated and/or had diarrhoea quite a bit 
You were constipated and/or had diarrhoea very much
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Table 6: Estimated preference weights 
Dimensions 
and levels 
(1) 
OLS 
(2) 
MLE 
RE 
(3) 
ERUM 
OLS 
(4) 
Mean 
model 
 (5) 
Consistent mean 
model 
PF2 0.061 0.052 0.052 0.065 PF2 0.065 
PF3 0.076 0.079 0.077 0.078 PF3 0.078 
PF4 0.135 0.134 0.103 0.139 PF45 0.127 
PF5 0.121 0.127 0.104 0.105   
RF2 0.026 0.023 0.044 0.032 RF2 0.032 
RF3 0.042 0.052 0.050 0.045 RF3 0.045 
RF4 0.082 0.090 0.076 0.079 RF4 0.078 
PAIN2 0.059 0.041 0.054 0.059 PAIN2 0.059 
PAIN3 0.060 0.060 0.064 0.062 PAIN3 0.062 
PAIN4 0.070 0.083 0.070 0.065 PAIN4 0.064 
EF2 0.028 0.027 0.032 0.030 EF2 0.030 
EF3 0.063 0.072 0.053 0.066 EF3 0.066 
EF4 0.157 0.160 0.132 0.150 EF4 0.149 
SF2 0.025 0.022 0.029 0.027 SF2 0.027 
SF3 0.059 0.065 0.046 0.059 SF3 0.059 
SF4 0.173 0.174 0.132 0.163 SF4 0.163 
FAT2 0.046 0.026 0.038 0.046 FAT2 0.047 
FAT3 0.052 0.031 0.052 0.054 FAT3 0.054 
FAT4 0.104 0.064 0.084 0.093 FAT4 0.092 
NAU2 0.031 0.036 0.025 0.032 NAU23 0.026 
NAU3 0.015 0.037 0.027 0.019   
NAU4 0.062 0.079 0.052 0.057 NAU4 0.056 
CD2 0.012 0.022 0.011 0.016 CD2 0.016 
CD3 0.050 0.037 0.035 0.052 CD3 0.052 
CD4 0.078 0.070 0.059 0.073 CD4 0.072 
       
Observations 2710 2710 2710 85  85  
 
R-squared 0.60  0.56 0.97  0.97 
Number of id  344     
Inconsistencies 2 1 0 2  0 
Insignificant 
level 
coefficients 
5 5 3 6  5 
MAE 0.052 0.054 0.046 0.050  0.051 
MAE>0.05 41 41 33 37  39 
MAE>-0.10 9 13 6 8  9 
 
Note: Figures in bold have t-statistics significant at the 5% level 
PF=Physical functioning, RF=Role functioning, PAIN=Pain, EF=Emotional functioning, SF=Social 
functioning, FAT=Fatigue, NAU=Nausea, CD=Constipation and/or diarrhoea. PF23=Physical 
functioning at level 2 or 3, NAU23=Nausea at level 2 or 3.
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Figure 1: Item map for physical functioning, role functioning and pain 
dimension  
 
 
 
 
 
